Imagine a vaccine that doesn't prevent a disease, but treats it. That’s the frontier a Hyderabad startup is exploring for cancer, one of the world's most challenging diseases. PopVax is developing personalised vaccines to fight cancer.
A 'Wanted Poster' for Cancer
Most vaccines we
know, like those for measles or COVID-19, are prophylactic—they prevent you from getting sick. Therapeutic cancer vaccines work differently. They are given to people who already have cancer to train their own immune system to find and destroy cancerous cells. Think of it as creating a custom 'wanted poster' for your specific cancer. The vaccine shows your immune system unique markers, called neoantigens, that are present only on tumour cells. This allows the body’s natural defences to launch a precise attack on the cancer while sparing healthy tissue, a major departure from the broader, more damaging effects of chemotherapy.
Meet PopVax: Hyderabad's Biotech Hope
At the centre of this development in India is PopVax, a Hyderabad-based startup founded in 2021 by computer scientist Soham Sankaran. After leaving his PhD program at Cornell University and founding a software startup, Sankaran transitioned into biotechnology, driven in part by his own family's experience with pancreatic cancer. PopVax brings together a team of global experts in immunology, mRNA technology, and machine learning. The company recently launched the 'RNA Foundry', a facility in Hyderabad for the research, development, and manufacturing of these advanced therapies.
The 'Personalised' mRNA Promise
The core of PopVax's strategy is making the treatment 'personal'. No two cancers are genetically identical. The process begins by taking a sample of a patient's tumour and sequencing its DNA to identify its unique mutations. This is where artificial intelligence comes in. PopVax uses machine learning algorithms to analyse this genetic data and predict which neoantigens will trigger the strongest immune response. Once the best targets are identified, a custom vaccine is created using messenger RNA (mRNA) technology, the same platform that became famous during the COVID-19 pandemic. The mRNA instructs the patient's own cells to produce the selected neoantigens, training the immune system for its fight against the cancer.
The Long and Winding Road to Approval
The headline's final words—'Without An Approved Cancer Treatment Yet'—are critical. While the science is incredibly promising, personalised cancer vaccines are still experimental. The journey from the lab to a widely available treatment is long and filled with challenges. The process of creating a unique vaccine for every single patient is complex and expensive. Each candidate must go through rigorous clinical trials to prove it is both safe and effective. PopVax has indicated its cancer vaccines have not yet been administered to patients and it plans to start with small groups outside India through special access pathways, subject to regulatory approvals. This is a marathon, not a sprint.
Why This Matters for India
Having an Indian company at the forefront of this global biotech race is significant. PopVax's work contributes to building a domestic ecosystem for complex therapies like mRNA medicines. One of the company's notable innovations is an mRNA platform designed to be stable at normal refrigerator temperatures, which could solve major logistical hurdles in distributing such advanced medicines in the future. While routine clinical use is still years away, the development of these technologies in India holds the longterm promise of making cuttingedge cancer treatments more accessible and affordable for the population. It signals a shift for the nation, from being a manufacturer of drugs to an innovator of new therapies.
